Genmab (GMAB) Fuels Confidence Based on Upcoming Epkinly and Petosemtamab Readouts

Core Insights - Genmab A/S (NASDAQ:GMAB) is identified as one of the 15 large cap stocks under $30 with significant upside potential, with a projected median 1-year price target of $39.25, indicating an upside of almost 53% from current levels [1] - Wells Fargo initiated coverage on Genmab A/S with an Overweight rating and a target price of $40, suggesting an upside potential of nearly 56% [2] - The company is expected to have pivotal developments in 2026, particularly regarding the upcoming readouts for Epkinly and petosemtamab, which are considered substantially de-risked [3] Analyst Ratings - Consensus sentiment for Genmab A/S remains strongly bullish, with 9 analysts covering the stock, 7 of whom have assigned Buy ratings and 2 Hold ratings, with no Sell ratings present [1] - Guggenheim analyst Michael Schmidt reduced the target price from $45 to $40 while maintaining a Buy rating, citing a deflated outlook for Epkinly in the near term [4] Company Overview - Genmab A/S is a biotechnology company based in Denmark, focused on developing antibodies and related products for cancer and other diseases, with marketed products including EPKINLY, TEPKINLY, and Tivdak [5]